Figure 1.

An overview of human γδ T cell-based immunotherapies and epigenetic inhibitors used in the clinics. (A). Clinical studies in patients with various malignancies are based on in vivo activation of γδ T cells (top) or adaptive immune transfer (bottom), or a combination thereof (left). (B). Use of DNMT (top) and HDAC inhibitors (bottom) for monotherapy or as a combination therapy (middle) in cancer patients. Ongoing or finished clinical trials are indicated with references, otherwise with respective identifiers adopted from US National Institutes of Health website (http://ClinicalTrials.gov) as of December 12, 2014. Zol, zoledronate.